Mar 07, 2022 / 03:30PM GMT
Operator
Good morning, and welcome to the Palatin Technologies KOL webinar on dry eye disease. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Palatin website following the conclusion of the event.
I'd now like to turn the call over to your host, Carl Spana, Chief Executive Officer of Palatin Technologies. Please go ahead, Carl.
Carl Spana - Palatin Technologies, Inc. - Co-Founder, President, CEO & Director
Thank you, Sara. Good morning, and welcome, everyone, to the Palatin Dry Eye Disease webinar.
We've designed a very nice seminar today. We have Dr. Eric D. Donnenfeld, who will start with covering what dry disease is, how he manages it, current treatments for dry eye disease and the unmet medical need, and some of the recently approved treatments. We'll follow it up with Dr. Michael Raizman, who will cover treatments in development and then we will focus on PL9643, Palatin's melanocortin agonist, which is in Phase III development as a treating -- for treating dry eye disease, and
Palatin Technologies Inc To Host Key Opinion Leader Webinar Transcript
Mar 07, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers